RU2017127273A - Короткие антимикробные липопептиды - Google Patents

Короткие антимикробные липопептиды Download PDF

Info

Publication number
RU2017127273A
RU2017127273A RU2017127273A RU2017127273A RU2017127273A RU 2017127273 A RU2017127273 A RU 2017127273A RU 2017127273 A RU2017127273 A RU 2017127273A RU 2017127273 A RU2017127273 A RU 2017127273A RU 2017127273 A RU2017127273 A RU 2017127273A
Authority
RU
Russia
Prior art keywords
lysine
palmitoyl
pal
lipid
proline
Prior art date
Application number
RU2017127273A
Other languages
English (en)
Inventor
Лицзюань ЧЖАН
Робин КАРМАЙКЛ
Original Assignee
Хеликс Байомедикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хеликс Байомедикс Инк. filed Critical Хеликс Байомедикс Инк.
Publication of RU2017127273A publication Critical patent/RU2017127273A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Birds (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Claims (11)

1. Способ лечения раны у млекопитающего, включающий применение к поврежденной ткани кожи терапевтически эффективного количества композиции, содержащей по меньшей мере один пептид формулы:
Pal-липид-лизин-пролин-NH2;
Pal-липид-лизин-гистидин-NH2 или
Pal-липид-лизин-аргинин-NH2; и
фармацевтически приемлемый носитель.
2. Способ по п.1, где поврежденная ткань кожи представляет собой гипертрофическое рубцевание, розацеа или экзематозные поражения.
3. Способ по п.2, где гипертрофическое рубцевание вызвано акне, фолликулитом, ожоговыми ранами, травматическими повреждениями, хирургическими процедурами или инфекцией кожи, вызванной микробами.
4. Способ по п.1, где пептид представляет собой
пальмитоил-лизин-пролин-NH2;
пальмитоил-лизин-гистидин-NH2; или
пальмитоил-лизин-аргинин-NH2.
RU2017127273A 2012-03-20 2013-03-07 Короткие антимикробные липопептиды RU2017127273A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613212P 2012-03-20 2012-03-20
US61/613,212 2012-03-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014142038A Division RU2627648C2 (ru) 2012-03-20 2013-03-07 Короткие антимикробные липопептиды

Publications (1)

Publication Number Publication Date
RU2017127273A true RU2017127273A (ru) 2019-02-04

Family

ID=47901428

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014142038A RU2627648C2 (ru) 2012-03-20 2013-03-07 Короткие антимикробные липопептиды
RU2017127273A RU2017127273A (ru) 2012-03-20 2013-03-07 Короткие антимикробные липопептиды

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2014142038A RU2627648C2 (ru) 2012-03-20 2013-03-07 Короткие антимикробные липопептиды

Country Status (19)

Country Link
US (1) US9278994B2 (ru)
EP (1) EP2827907B1 (ru)
JP (1) JP6261560B2 (ru)
KR (1) KR20140136494A (ru)
CN (2) CN104379177B (ru)
AR (1) AR090439A1 (ru)
AU (1) AU2013235692B2 (ru)
CA (1) CA2864179A1 (ru)
DK (1) DK2827907T3 (ru)
ES (1) ES2729237T3 (ru)
HK (1) HK1204453A1 (ru)
MX (1) MX2014011290A (ru)
MY (1) MY163100A (ru)
PL (1) PL2827907T3 (ru)
RU (2) RU2627648C2 (ru)
SG (2) SG11201405244RA (ru)
TW (1) TWI541254B (ru)
WO (1) WO2013142088A1 (ru)
ZA (1) ZA201405950B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6906274B2 (ja) * 2014-06-30 2021-07-21 ロート製薬株式会社 外用組成物、眼科用組成物、抗菌剤、及び抗菌方法
EP3210613A4 (en) 2014-06-30 2018-08-22 Rohto Pharmaceutical Co., Ltd. Composition for external application
WO2017035345A1 (en) * 2015-08-26 2017-03-02 The General Hospital Corporation System and method for electrical control of bacteria
KR101855170B1 (ko) * 2015-11-18 2018-05-08 (주)노바셀테크놀로지 신규 항균 펩타이드 및 그의 용도
CN109320585B (zh) * 2018-09-06 2021-10-26 南方医科大学 一种具有专一性抗痤疮丙酸杆菌作用及抗炎作用的短脂肽
CA3112268A1 (en) * 2018-09-12 2020-03-19 The Governing Council Of The University Of Toronto Indole-oxadiazole compounds and their therapeutic use
CN111035764B (zh) * 2018-10-14 2021-09-07 深圳市健元医药科技有限公司 一种治疗类风湿性关节炎的组合物及其制备方法
CN110279844A (zh) * 2019-01-31 2019-09-27 浙江星杭泰乐生物医药有限公司 人工合成抗菌肽在制备抑菌消炎祛痘化妆品或外用药物制剂中的应用及抑菌消炎祛痘组合物
CN111303242B (zh) * 2020-02-27 2022-04-26 广州领晟医疗科技有限公司 一种KdPT的修饰肽
KR102163568B1 (ko) * 2020-08-21 2020-10-07 주식회사 비드테크 지방산 항균펩타이드 및 이를 함유하는 항균 조성물
US11793746B2 (en) * 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
CN112679576B (zh) * 2020-11-06 2022-09-20 黄石瀚海新材料科技有限公司 抗菌脂肽、抗菌脂肽水凝胶制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230500D1 (de) * 1991-10-28 2000-02-03 Cytran Ltd Pharmazeutische Dipeptid Zusammensetzungen und Verwendungsmethoden.
JP3273314B2 (ja) * 1998-08-12 2002-04-08 独立行政法人農業生物資源研究所 抗菌ペプチド及びこれを有効成分とする抗菌剤
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
WO2004110341A2 (en) * 2003-06-19 2004-12-23 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
CN1893911B (zh) * 2003-11-17 2010-12-29 赛德玛公司 含有四肽和三肽混合物的配方
FR2870244B1 (fr) * 2004-05-11 2011-01-07 Centre Nat Rech Scient Conjugues dipeptidiques antagonistes de l'alpha-msh
DE102004055541A1 (de) * 2004-11-17 2006-05-18 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer Haut
US20100215726A1 (en) * 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
CN102329375A (zh) * 2011-09-30 2012-01-25 中国药科大学 一组末端酰胺化的抗菌肽

Also Published As

Publication number Publication date
WO2013142088A1 (en) 2013-09-26
RU2014142038A (ru) 2016-05-10
TW201339176A (zh) 2013-10-01
TWI541254B (zh) 2016-07-11
ES2729237T3 (es) 2019-10-31
AR090439A1 (es) 2014-11-12
DK2827907T3 (da) 2019-06-11
US9278994B2 (en) 2016-03-08
EP2827907B1 (en) 2019-03-06
JP6261560B2 (ja) 2018-01-17
ZA201405950B (en) 2017-08-30
KR20140136494A (ko) 2014-11-28
CN104379177B (zh) 2017-07-04
CN107080831A (zh) 2017-08-22
AU2013235692A1 (en) 2014-09-25
AU2013235692B2 (en) 2016-12-08
RU2627648C2 (ru) 2017-08-09
SG10201607784VA (en) 2016-11-29
SG11201405244RA (en) 2014-10-30
HK1204453A1 (en) 2015-11-20
CN104379177A (zh) 2015-02-25
CA2864179A1 (en) 2013-09-26
PL2827907T3 (pl) 2019-08-30
US20150080291A1 (en) 2015-03-19
JP2015512386A (ja) 2015-04-27
EP2827907A1 (en) 2015-01-28
MX2014011290A (es) 2014-10-13
MY163100A (en) 2017-08-04

Similar Documents

Publication Publication Date Title
RU2017127273A (ru) Короткие антимикробные липопептиды
CO6680670A2 (es) Agonistas de ep4 prostaglandina útiles en la preparación de lal piel y la cicatrización de heridas
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
RU2013121788A (ru) Ингибиторы репликации вич
CL2012003470A1 (es) Una composicion solida que comprende 1) un compuesto inhibidor del hcv de formula definida, o una sal farmaceuticamente aceptable de este, en una forma amorfa, 2) un polimero hidrofilico, y opcionalmente 3) un agente tensoactivo; su proceso de preparacion, util para tratar una infeccion del hcv.
BR112012030261A2 (pt) nova composição farmacêutica sinergística para a preparação de formulações tópicas para a pofilaxia e tratamento de feridas, feridas por queimaduras, exertos de pele, úlceras de pressão e úlceras do pé diabético
WO2011127188A3 (en) Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций
BR112012028451A2 (pt) composição tópica de iodopovidona
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
JP2015512386A5 (ru)
WO2010079209A3 (en) Compositions for treating wounds and skin conditions
JP2017514866A5 (ru)
CO7240418A2 (es) Apósito con una liberación prolongada de agentes activos
WO2009016629A3 (en) Pharmaceutical composition for treating wounds and related methods
GB2476446A (en) Topical treatment of skin infection
EA201590546A1 (ru) Способы лечения заболеваний, связанных с волосами
RU2009107068A (ru) Применение пропиленгликоля при лечении связанных с воспалением местных нарушений или заболеваний и ран
CO6761349A2 (es) Proteína antimicrobiana
RU2011136311A (ru) Фармацевтические композиции для обезвоживания, атрофии и удаления патологических тканей
WO2014182610A3 (en) Alpha adrenergic agonists for in the treatment of tissue trauma
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
RU2015148636A (ru) Модуляция активности гепарин-связывающего эпидермального фактора роста для заживления барабанной перепонки
RU2015142443A (ru) Синергетическая комбинация аланин-глутамина, гиалуроновой кислоты и экстракта овса и ее применение в композиции для заживления ран и восстановления повреждений кожи

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20200803